Phagelux, Inc.

Wuhan Phagelux Bio-Tech Company Limited

Hongping Wei

Hang Yang

Junping Yu

Jing Wang

The present invention discloses a lysin that is capable of killingand the use thereof, belonging to the field of biological agents. The present invention discloses the amino acid sequence and the encoding gene sequence of the lysin. This lysin keeps active in a wide range of pH. It has lytic activity againstin pH 4-11. The recombinant protease constructed by the encoding gene can be solubly expressed instrain BL21 (DE3). The lysin can be used to effectively kill multiple speciesin vitro, including methicillin sensitive(MSSA) and methicillin resistant(MRSA) isolated in clinics. This lysin can be used as an antibiotic for the treatment of staphylococcal infections in vivo. This lysin is also able to rapidly lyse staphylococcal cell wall; as a result, intracellular substances such as ATP and DNA are released. Those released substances can be used to detect the type of

Staphylococcus lysin and use thereof

This invention discloses a lysin that can kill many species of Streptococci. A new lysin, ClyR, was constructed by the gene splicing method. The ClyR can effectively kill different species of Streptococci, including, and various Enterococci and. ClyR shows good stability and is not sensitive to EDTA and high concentration of NaCl. Moreover, the ClyR is active in a wide range of pH and maintains high activity in pH 5-11. Recombinant protein ClyR is well expressed instain BL21 (DE3). High doses of ClyR showed no apparent toxicity in mice. Furthermore, administration of 0.8 mg per mouse once is able to completely protect the mouse infected with lethal doses of Group B Streptococci. The ClyR can be used alone or in combination with different forms of reagents and solutions, for the control of a variety of Streptococci and for the treatment of infections caused by these bacteria. It has a broad application prospect.

Growing community of inventors

Wuhan, China

Hongping Wei